Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.

Yoshioka T, Shien K, Takeda T, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Soh J, Fujiwara T, Toyooka S.

Cancer Sci. 2019 Aug;110(8):2549-2557. doi: 10.1111/cas.14089. Epub 2019 Jun 24.

2.

Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness.

Chen Y, Sumardika IW, Tomonobu N, Kinoshita R, Inoue Y, Iioka H, Mitsui Y, Saito K, Ruma IMW, Sato H, Yamauchi A, Murata H, Yamamoto KI, Tomida S, Shien K, Yamamoto H, Soh J, Futami J, Kubo M, Putranto EW, Murakami T, Liu M, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Neoplasia. 2019 Jul;21(7):627-640. doi: 10.1016/j.neo.2019.04.006. Epub 2019 May 14.

3.

Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.

Kurihara E, Shien K, Torigoe H, Takeda T, Takahashi Y, Ogoshi Y, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Okazaki M, Shien T, Tomida S, Toyooka S.

Anticancer Res. 2019 Apr;39(4):1767-1775. doi: 10.21873/anticanres.13283.

PMID:
30952716
4.

Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma.

Sato H, Soh J, Aoe K, Fujimoto N, Tanaka S, Namba K, Torigoe H, Shien K, Yamamoto H, Tomida S, Tao H, Okabe K, Kishimoto T, Toyooka S.

Int J Oncol. 2019 Jun;54(6):2139-2148. doi: 10.3892/ijo.2019.4768. Epub 2019 Apr 1.

PMID:
30942424
5.

Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.

Chen Y, Sumardika IW, Tomonobu N, Winarsa Ruma IM, Kinoshita R, Kondo E, Inoue Y, Sato H, Yamauchi A, Murata H, Yamamoto KI, Tomida S, Shien K, Yamamoto H, Soh J, Liu M, Futami J, Sasai K, Katayama H, Kubo M, Putranto EW, Hibino T, Sun B, Nishibori M, Toyooka S, Sakaguchi M.

Cancer Lett. 2019 Jun 28;452:178-190. doi: 10.1016/j.canlet.2019.03.023. Epub 2019 Mar 21.

6.

Pulmonary resection in a prone position for lung cancer invading the spine.

Miyauchi S, Soh J, Shien K, Tanaka M, Yamamoto H, Ozaki T, Toyooka S.

Gen Thorac Cardiovasc Surg. 2019 Mar 21. doi: 10.1007/s11748-019-01113-7. [Epub ahead of print]

PMID:
30903520
7.

Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations.

Ogoshi Y, Shien K, Yoshioka T, Torigoe H, Sato H, Sakaguchi M, Tomida S, Namba K, Kurihara E, Takahashi Y, Suzawa K, Yamamoto H, Soh J, Toyooka S.

Oncol Lett. 2019 Mar;17(3):2729-2736. doi: 10.3892/ol.2019.9908. Epub 2019 Jan 8.

8.

Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naïve lung adenocarcinoma.

Namba K, Tomida S, Matsubara T, Takahashi Y, Kurihara E, Ogoshi Y, Yoshioka T, Takeda T, Torigoe H, Sato H, Shien K, Yamamoto H, Soh J, Tsukuda K, Toyooka S.

BMC Cancer. 2019 Feb 26;19(1):175. doi: 10.1186/s12885-019-5374-1.

9.

Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy.

Suzawa K, Soh J, Takahashi Y, Sato H, Shien K, Yamamoto H, Kanazawa S, Kiura K, Miyoshi S, Toyooka S.

Surg Today. 2019 Jul;49(7):601-609. doi: 10.1007/s00595-019-1774-8. Epub 2019 Feb 8.

PMID:
30734881
10.

Neuroplastin-β mediates S100A8/A9-induced lung cancer disseminative progression.

Sumardika IW, Chen Y, Tomonobu N, Kinoshita R, Ruma IMW, Sato H, Kondo E, Inoue Y, Yamauchi A, Murata H, Yamamoto KI, Tomida S, Shien K, Yamamoto H, Soh J, Futami J, Putranto EW, Hibino T, Nishibori M, Toyooka S, Sakaguchi M.

Mol Carcinog. 2019 Jun;58(6):980-995. doi: 10.1002/mc.22987. Epub 2019 Feb 27.

PMID:
30720226
11.

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Cells.

Namba K, Shien K, Takahashi Y, Torigoe H, Sato H, Yoshioka T, Takeda T, Kurihara E, Ogoshi Y, Yamamoto H, Soh J, Tomida S, Toyooka S.

Mol Cancer Res. 2019 Feb;17(2):499-507. doi: 10.1158/1541-7786.MCR-18-0628. Epub 2018 Nov 21.

PMID:
30463991
12.

Newly developed anti-S100A8/A9 monoclonal antibody efficiently prevents lung tropic cancer metastasis.

Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW, Chen Y, Tomonobu N, Araki K, Shien K, Tomida S, Torigoe H, Namba K, Kurihara E, Ogoshi Y, Murata H, Yamamoto KI, Futami J, Putranto EW, Ruma IMW, Yamamoto H, Soh J, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Int J Cancer. 2019 Jul 15;145(2):569-575. doi: 10.1002/ijc.31982. Epub 2018 Dec 14.

PMID:
30414170
13.

exSSSRs (extracellular S100 soil sensor receptors)-Fc fusion proteins work as prominent decoys to S100A8/A9-induced lung tropic cancer metastasis.

Kinoshita R, Sato H, Yamauchi A, Takahashi Y, Inoue Y, Sumardika IW, Chen Y, Tomonobu N, Araki K, Shien K, Tomida S, Torigoe H, Namba K, Kurihara E, Ogoshi Y, Murata H, Yamamoto KI, Futami J, Putranto EW, Ruma IMW, Yamamoto H, Soh J, Hibino T, Nishibori M, Kondo E, Toyooka S, Sakaguchi M.

Int J Cancer. 2019 Jun 15;144(12):3138-3145. doi: 10.1002/ijc.31945. Epub 2018 Dec 4.

PMID:
30365872
14.

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer.

Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG.

Oncotarget. 2018 Sep 21;9(74):33995-34008. doi: 10.18632/oncotarget.26129. eCollection 2018 Sep 21.

15.

Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis.

Takahashi Y, Shien K, Tomida S, Oda S, Matsubara T, Sato H, Suzawa K, Kurihara E, Ogoshi Y, Namba K, Yoshioka T, Torigoe H, Yamamoto H, Soh J, Toyooka S.

Cancer Sci. 2018 Nov;109(11):3634-3642. doi: 10.1111/cas.13797. Epub 2018 Oct 6.

16.

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.

Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.

Cancer Sci. 2018 Oct;109(10):3183-3196. doi: 10.1111/cas.13763. Epub 2018 Sep 14.

17.

Myoepithelioma occurring in the posterior mediastinum harboring EWSR1 rearrangement: a case report.

Habu T, Soh J, Toji T, Shien K, Niman E, Namba K, Sato H, Yamamoto H, Sugimoto S, Yamane M, Toyooka S.

Jpn J Clin Oncol. 2018 Sep 1;48(9):851-854. doi: 10.1093/jjco/hyy100.

PMID:
30053180
18.

[Induction Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer].

Miura A, Soh J, Shien K, Yamamoto H, Toyooka S.

Kyobu Geka. 2018 Apr;71(4):270-277. Japanese.

PMID:
29755100
19.

Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.

Torigoe H, Yamamoto H, Sakaguchi M, Youyi C, Namba K, Sato H, Shien K, Soh J, Suzawa K, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.

Carcinogenesis. 2018 May 3;39(5):719-727. doi: 10.1093/carcin/bgy044.

PMID:
29546323
20.

Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.

Torigoe H, Shien K, Takeda T, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Sakaguchi M, Tomida S, Tsukuda K, Miyoshi S, Toyooka S.

Cancer Sci. 2018 May;109(5):1493-1502. doi: 10.1111/cas.13571. Epub 2018 Apr 15.

21.

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer.

Yoshioka T, Shien K, Namba K, Torigoe H, Sato H, Tomida S, Yamamoto H, Asano H, Soh J, Tsukuda K, Nagasaka T, Fujiwara T, Toyooka S.

Cancer Sci. 2018 Apr;109(4):1166-1176. doi: 10.1111/cas.13546. Epub 2018 Mar 25.

22.

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.

Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.

Oncogenesis. 2018 Jan 24;7(1):11. doi: 10.1038/s41389-017-0017-3.

23.

Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer.

Torigoe H, Soh J, Tomida S, Namba K, Sato H, Katsui K, Hotta K, Shien K, Yamamoto H, Yamane M, Kanazawa S, Kiura K, Miyoshi S, Toyooka S.

J Thorac Dis. 2017 Sep;9(9):3076-3086. doi: 10.21037/jtd.2017.08.87.

24.

Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer.

Chen H, Shien K, Suzawa K, Tsukuda K, Tomida S, Sato H, Torigoe H, Watanabe M, Namba K, Yamamoto H, Soh J, Asano H, Miyoshi S, Toyooka S.

Oncol Lett. 2017 Oct;14(4):4349-4354. doi: 10.3892/ol.2017.6678. Epub 2017 Jul 26.

25.

β-1,3-Galactosyl-O-Glycosyl-Glycoprotein β-1,6-N-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer Motility.

Sumardika IW, Youyi C, Kondo E, Inoue Y, Ruma IMW, Murata H, Kinoshita R, Yamamoto KI, Tomida S, Shien K, Sato H, Yamauchi A, Futami J, Putranto EW, Hibino T, Toyooka S, Nishibori M, Sakaguchi M.

Oncol Res. 2018 Apr 10;26(3):431-444. doi: 10.3727/096504017X15031557924123. Epub 2017 Sep 18.

PMID:
28923134
26.

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG.

Mol Cancer Ther. 2017 Oct;16(10):2234-2245. doi: 10.1158/1535-7163.MCT-17-0148. Epub 2017 Jul 20.

27.

Is tumor location an independent prognostic factor in locally advanced non-small cell lung cancer treated with trimodality therapy?

Shien K, Toyooka S, Soh J, Yamamoto H, Miyoshi S.

J Thorac Dis. 2017 May;9(5):E489-E491. doi: 10.21037/jtd.2017.03.183. No abstract available.

28.

Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin.

Sato H, Toyooka S, Soh J, Hotta K, Katsui K, Shien K, Yamamoto H, Oto T, Kanazawa S, Kiura K, Miyoshi S.

Ann Thorac Surg. 2017 Sep;104(3):971-978. doi: 10.1016/j.athoracsur.2017.03.045. Epub 2017 Jun 11.

PMID:
28610882
29.

Erratum to "Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer" [Lung Cancer 76 (1) (2012) 32-38].

Tanaka N, Toyooka S, Soh J, Kubo T, Yamamoto H, Maki Y, Muraoka T, Shien K, Furukawa M, Ueno T, Asano H, Tsukuda K, Aoe K, Miyoshi S.

Lung Cancer. 2017 Jun;108:254-255. doi: 10.1016/j.lungcan.2016.04.016. Epub 2017 Apr 27. No abstract available.

PMID:
28457607
30.

Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.

Takeda T, Yamamoto H, Kanzaki H, Suzawa K, Yoshioka T, Tomida S, Cui X, Murali R, Namba K, Sato H, Torigoe H, Watanabe M, Shien K, Soh J, Asano H, Tsukuda K, Kitamura Y, Miyoshi S, Sendo T, Toyooka S.

PLoS One. 2017 Feb 3;12(2):e0171356. doi: 10.1371/journal.pone.0171356. eCollection 2017. Erratum in: PLoS One. 2017 Mar 16;12 (3):e0174493.

31.

Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features.

Sato H, Shien K, Tomida S, Okayasu K, Suzawa K, Hashida S, Torigoe H, Watanabe M, Yamamoto H, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S.

Sci Rep. 2017 Jan 13;7:40847. doi: 10.1038/srep40847.

32.

Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies.

Suzawa K, Shien K, Peng H, Sakaguchi M, Watanabe M, Hashida S, Maki Y, Yamamoto H, Tomida S, Soh J, Asano H, Tsukuda K, Nasu Y, Kumon H, Miyoshi S, Toyooka S.

Anticancer Res. 2017 Jan;37(1):301-307.

PMID:
28011506
33.

Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.

Ohtsuka T, Sakaguchi M, Yamamoto H, Tomida S, Takata K, Shien K, Hashida S, Miyata-Takata T, Watanabe M, Suzawa K, Soh J, Youyi C, Sato H, Namba K, Torigoe H, Tsukuda K, Yoshino T, Miyoshi S, Toyooka S.

Sci Rep. 2016 Dec 23;6:39557. doi: 10.1038/srep39557.

34.

Role of surgery in N2 NSCLC: pros.

Shien K, Toyooka S.

Jpn J Clin Oncol. 2016 Dec;46(12):1168-1173. Epub 2016 Sep 21.

PMID:
27655902
35.

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.

Shien K, Papadimitrakopoulou VA, Wistuba II.

Lung Cancer. 2016 Sep;99:79-87. doi: 10.1016/j.lungcan.2016.06.016. Epub 2016 Jun 21. Review.

36.

Study about the Efficacy of Metformin to Immune Function in Cancer Patients.

Watanabe M, Yamamoto H, Eikawa S, Shien K, Shien T, Soh J, Hotta K, Wada J, Hinotsu S, Fujiwara T, Kiura K, Doihara H, Miyoshi S, Udono H, Toyooka S.

Acta Med Okayama. 2016 Aug;70(4):327-30.

37.

The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells.

Maki Y, Nishimura Y, Toyooka S, Soh J, Tsukuda K, Shien K, Furukawa M, Muraoka T, Ueno T, Tanaka N, Yamamoto H, Asano H, Maeda M, Kumagai-Takei N, Lee S, Matsuzaki H, Otsuki T, Miyoshi S.

Oncol Lett. 2016 May;11(5):3308-3316. Epub 2016 Apr 5.

38.

Genetic alterations in lung adenocarcinoma with a micropapillary component.

Furukawa M, Toyooka S, Ichimura K, Yamamoto H, Soh J, Hashida S, Ouchida M, Shien K, Asano H, Tsukuda K, Miyoshi S.

Mol Clin Oncol. 2016 Feb;4(2):195-200. Epub 2015 Dec 2.

39.

Establishment and molecular characterization of cell lines from Japanese patients with malignant pleural mesothelioma.

Suzawa K, Yamamoto H, Murakami T, Katayama H, Furukawa M, Shien K, Hashida S, Okabe K, Aoe K, Soh J, Asano H, Tsukuda K, Mimura Y, Toyooka S, Miyoshi S.

Oncol Lett. 2016 Jan;11(1):705-712. Epub 2015 Nov 23.

40.

DNA copy number gains in malignant pleural mesothelioma.

Furukawa M, Toyooka S, Hayashi T, Yamamoto H, Fujimoto N, Soh J, Hashida S, Shien K, Asano H, Aoe K, Okabe K, Pass HI, Tsukuda K, Kishimoto T, Miyoshi S.

Oncol Lett. 2015 Nov;10(5):3274-3278. Epub 2015 Aug 27.

41.

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.

Hashida S, Yamamoto H, Shien K, Miyoshi Y, Ohtsuka T, Suzawa K, Watanabe M, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S.

Cancer Sci. 2015 Oct;106(10):1377-84. doi: 10.1111/cas.12749. Epub 2015 Sep 30.

42.

Lower lobe origin is a poor prognostic factor in locally advanced non-small-cell lung cancer patients treated with induction chemoradiotherapy.

Shien K, Toyooka S, Soh J, Hotta K, Katsui K, Oto T, Kanazawa S, Kiura K, Date H, Miyoshi S.

Mol Clin Oncol. 2015 May;3(3):706-712. Epub 2015 Feb 11.

43.

Clinicopathological characteristics and lymph node metastasis pathway of non-small-cell lung cancer located in the left lingular division.

Shien K, Toyooka S, Soh J, Okami J, Higashiyama M, Kadota Y, Maeda H, Hayama M, Chida M, Funaki S, Okumura M, Miyoshi S.

Interact Cardiovasc Thorac Surg. 2015 Jun;20(6):791-6. doi: 10.1093/icvts/ivv062. Epub 2015 Mar 24.

PMID:
25805399
44.

Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.

Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, Furukawa M, Soh J, Asano H, Tsukuda K, Miyoshi S, Kanazawa S, Toyooka S.

Oncol Rep. 2015 Mar;33(3):1499-504. doi: 10.3892/or.2015.3735. Epub 2015 Jan 20.

PMID:
25607753
45.

Extended sleeve lobectomy after induction chemoradiotherapy for non-small cell lung cancer.

Toyooka S, Soh J, Yamamoto H, Yamane M, Hattori S, Shien K, Miyoshi K, Sugimoto S, Oto T, Miyoshi S.

Surg Today. 2015 Sep;45(9):1121-6. doi: 10.1007/s00595-014-1025-y. Epub 2014 Sep 12.

PMID:
25212567
46.

Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer.

Shien K, Yamamoto H, Soh J, Miyoshi S, Toyooka S.

Acta Med Okayama. 2014;68(4):191-200. Review.

47.

Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients.

Hashida S, Soh J, Toyooka S, Tanaka T, Furukawa M, Shien K, Yamamoto H, Asano H, Tsukuda K, Hagiwara K, Miyoshi S.

Oncol Rep. 2014 Jul;32(1):145-52. doi: 10.3892/or.2014.3197. Epub 2014 May 16.

PMID:
24842519
48.

Density of tumor-infiltrating FOXP3+ T cells as a response marker for induction chemoradiotherapy and a potential prognostic factor in patients treated with trimodality therapy for locally advanced non-small cell lung cancer.

Tao H, Shien K, Soh J, Matsuda E, Toyooka S, Okabe K, Miyoshi S.

Ann Thorac Cardiovasc Surg. 2014;20(6):980-6. doi: 10.5761/atcs.oa.13-00237. Epub 2014 Feb 28.

49.

Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma.

Ueno T, Toyooka S, Fukazawa T, Kubo T, Soh J, Asano H, Muraoka T, Tanaka N, Maki Y, Shien K, Furukawa M, Sakaguchi M, Yamamoto H, Tsukuda K, Miyoshi S.

Acta Med Okayama. 2014;68(1):23-6.

50.

Anti-cancer effects of REIC/Dkk-3-encoding adenoviral vector for the treatment of non-small cell lung cancer.

Shien K, Tanaka N, Watanabe M, Soh J, Sakaguchi M, Matsuo K, Yamamoto H, Furukawa M, Asano H, Tsukuda K, Nasu Y, Huh NH, Miyoshi S, Kumon H, Toyooka S.

PLoS One. 2014 Feb 3;9(2):e87900. doi: 10.1371/journal.pone.0087900. eCollection 2014.

Supplemental Content

Support Center